ArticleBritish journal of pharmacology2012
3-Iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in mice.
Article in British journal of pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- Delivery of Thyronamines (TAMs) to the Brain: A Preliminary Study.Molecules (Basel, Switzerland) · 2021Article
- TAAR1 agonists attenuate extended-access cocaine self-administration and yohimbine-induced reinstatement of cocaine-seeking.British journal of pharmacology · 2020Article
- 3-Iodothyronamine and Derivatives: New Allies Against Metabolic Syndrome?International journal of molecular sciences · 2020Review
- The Colorful Diversity of Thyroid Hormone Metabolites.European thyroid journal · 2019Review
- Thyroid Hormone, Thyroid Hormone Metabolites and Mast Cells: A Less Explored Issue.Frontiers in cellular neuroscience · 2019Review
- Commentary: 3-Iodothyronamine Reduces Insulin Secretion In Vitro via a Mitochondrial Mechanism.Frontiers in endocrinology · 2018Article
- The Trace Amine-Associated Receptor 1 Agonist 3-Iodothyronamine Induces Biased Signaling at the Serotonin 1b Receptor.Frontiers in pharmacology · 2018Article
- Central Effects of 3-Iodothyronamine Reveal a Novel Role for Mitochondrial Monoamine Oxidases.Frontiers in endocrinology · 2018Review
- Thyroid Hormones, Thyromimetics and Their Metabolites in the Treatment of Liver Disease.Frontiers in endocrinology · 2018Review
- Similarities and Differences in the Peripheral Actions of Thyroid Hormones and Their Metabolites.Frontiers in endocrinology · 2018Review
- 3-Iodothyronamine Activates a Set of Membrane Proteins in Murine Hypothalamic Cell Lines.Frontiers in endocrinology · 2018Article
- Commentary: Torpor: The Rise and Fall of 3-Monoiodothyronamine from Brain to Gut-From Gut to Brain?Frontiers in endocrinology · 2017Article
- New Insights into the Potential Roles of 3-Iodothyronamine (T1AM) and Newly Developed Thyronamine-Like TAAR1 Agonists in Neuroprotection.Frontiers in pharmacology · 2017Article
- The Case for TAAR1 as a Modulator of Central Nervous System Function.Frontiers in pharmacology · 2017Review
- Inverse agonistic action of 3-iodothyronamine at the human trace amine-associated receptor 5.PloS one · 2015Article
- Histamine mediates behavioural and metabolic effects of 3-iodothyroacetic acid, an endogenous end product of thyroid hormone metabolism.British journal of pharmacology · 2014Article
- New avenues for regulation of lipid metabolism by thyroid hormones and analogs.Frontiers in physiology · 2014Review
- Modulation of gene expression by 3-iodothyronamine: genetic evidence for a lipolytic pattern.PloS one · 2014Article
- Update on 3-iodothyronamine and its neurological and metabolic actions.Frontiers in physiology · 2014Review
- NMR-based metabolomics and breath studies show lipid and protein catabolism during low dose chronic T(1)AM treatment.Obesity (Silver Spring, Md.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND PURPOSE Preclinical pharmacology of 3-iodothyronamine (T1AM), an endogenous derivative of thyroid hormones, indicates that it is a rapid modulator of rodent metabolism and behaviour. Since T1AM undergoes rapid enzymatic degradation, particularly by MAO, we hypothesized that the effects of T1AM might be altered by inhibition of MAO. EXPERIMENTAL APPROACH We investigated the effects of injecting T1AM (i.c.v.) on (i) feeding behaviour, hyperglycaemia and plasma levels of thyroid hormones and (ii) T1AM systemic bioavailability, in overnight fasted mice, under control conditions and after pretreatment with the MAO inhibitor clorgyline. T1AM (1.3, 6.6, 13, 20 and 26 µg·kg(-1) ) or vehicle were injected i.c.v. in fasted male mice not pretreated or pretreated i.p. with clorgyline (2.5 mg·kg(-1) ). Glycaemia was measured by a glucorefractometer, plasma triiodothyronine (fT3) by a chemiluminescent immunometric assay, c-fos activation immunohistochemically and plasma T1AM by HPLC coupled to tandem-MS. KEY RESULTS T1AM, 1.3 µg·kg(-1) , produced a hypophagic effect (-24% vs. control) and reduced c-fos activation. This dose showed systemic bioavailability (0.12% of injected dose), raised plasma glucose levels and reduced peripheral insulin sensitivity (-33% vs. control) and plasma fT3 levels. These effects were not linearly related to the dose injected. Clorgyline pretreatment strongly increased the systemic bioavailability of T1AM and prevented the hyperglycaemia and reduction in fT3 induced by T1AM. CONCLUSIONS AND IMPLICATIONS T1AM induces central and peripheral effects including hyperglycaemia and a reduction in plasma fT3 levels in fasted mice. These effects critically depend on the concentration of T1AM or its metabolites in target organs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.